Advanced Life Sciences Holdings Inc. is proceeding with its new drug application (NDA) for cethromycin in community-acquired pneumonia (CAP) after results of the second of two pivotal clinical trials showed that the ketolide antibiotic met its primary endpoint of statistical noninferiority cure rates. (BioWorld Today) Read More